Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Corcept Therapeutics Inc (NASDAQ: CORT) closed the day trading at $34.8 down -50.42% from the previous closing price of $70.19. In other words, the price has decreased by -$50.42 from its previous closing price. On the day, 20.27 million shares were traded. CORT stock price reached its highest trading level at $39.0 during the session, while it also had its lowest trading level at $32.9906.
Ratios:
For a better understanding of CORT, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.68 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 22.52. For the most recent quarter (mrq), Quick Ratio is recorded 3.07 and its Current Ratio is at 3.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 02 ’25 when Guyer William sold 20,000 shares for $80.08 per share. The transaction valued at 1,601,526 led to the insider holds 1,235 shares of the business.
Maduck Sean sold 20,000 shares of CORT for $1,590,490 on Dec 01 ’25. The insider now owns 7,904 shares after completing the transaction at $79.52 per share. On Dec 01 ’25, another insider, Lyon Joseph Douglas, who serves as the insider of the company, sold 5,000 shares for $79.53 each. As a result, the insider received 397,632 and left with 10,277 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 3666936064 and an Enterprise Value of 3245224960. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.76, and their Forward P/E ratio for the next fiscal year is 48.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.18. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.94 while its Price-to-Book (P/B) ratio in mrq is 5.79. Its current Enterprise Value per Revenue stands at 4.379 whereas that against EBITDA is 48.645.
Stock Price History:
The Beta on a monthly basis for CORT is 0.18, which has changed by -0.31576878 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, CORT has reached a high of $117.33, while it has fallen to a 52-week low of $49.00. The 50-Day Moving Average of the stock is -55.16%, while the 200-Day Moving Average is calculated to be -52.92%.
Shares Statistics:
Over the past 3-months, CORT traded about 896.00K shares per day on average, while over the past 10 days, CORT traded about 3114700 shares per day. A total of 105.12M shares are outstanding, with a floating share count of 93.21M. Insiders hold about 11.39% of the company’s shares, while institutions hold 74.70% stake in the company. Shares short for CORT as of 1765756800 were 10108719 with a Short Ratio of 11.28, compared to 1763078400 on 10166733. Therefore, it implies a Short% of Shares Outstanding of 10108719 and a Short% of Float of 12.989999999999998.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate. The current performance of Corcept Therapeutics Inc (CORT) in the stock market.The consensus estimate for the next quarter is $0.06, with high estimates of $0.34 and low estimates of -$0.12.
Analysts are recommending an EPS of between $1.18 and $0.57 for the fiscal current year, implying an average EPS of $0.87. EPS for the following year is $0.84, with 6.0 analysts recommending between $1.9 and -$0.93.
Revenue Estimates
5 analysts predict $246.11M in revenue for. The current quarter. It ranges from a high estimate of $265.72M to a low estimate of $197.3M. As of. The current estimate, Corcept Therapeutics Inc’s year-ago sales were $181.89MFor the next quarter, 5 analysts are estimating revenue of $214.19M. There is a high estimate of $233M for the next quarter, whereas the lowest estimate is $190M.
A total of 5 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $825M, while the lowest revenue estimate was $756.6M, resulting in an average revenue estimate of $805.38M. In the same quarter a year ago, actual revenue was $675.04MBased on 5 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.26B and the low estimate is $843.1M.
